Applied Therapeutics Inc APLT.OQ APLT.O is expected to show a rise in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
The New York City-based company is expected to report a 2,312.3% increase in revenue to $4.583 million from $190 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Applied Therapeutics Inc is for a loss of 19 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts had risen by about 9.1% in the last three months.
Wall Street's median 12-month price target for Applied Therapeutics Inc is $2.50, above its last closing price of $0.46.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.18 | 0.33 | Beat | 285.9 | |
Sep. 30 2024 | -0.16 | -0.16 | -0.48 | Missed | -203.8 |
Jun. 30 2024 | -0.15 | -0.16 | 0.02 | Beat | 112.2 |
Mar. 31 2024 | -0.16 | -0.16 | -0.67 | Missed | -320.1 |
Dec. 31 2023 | -0.20 | -0.23 | -0.34 | Missed | -49.1 |
Sep. 30 2023 | -0.23 | -0.26 | -0.47 | Missed | -81.2 |
Jun. 30 2023 | -0.17 | -0.26 | -0.37 | Missed | -39.6 |
Mar. 31 2023 | -0.27 | -0.31 | -0.18 | Beat | 41.3 |
This summary was machine generated May 5 at 13:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。